Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scinai Immunotherapeutics Ltd SCNI

Healthcare Biotechnology
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various... see more

Recent & Breaking News (NDAQ:SCNI)

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

PR Newswire 13 hours ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

PR Newswire May 24, 2024

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

PR Newswire May 15, 2024

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

PR Newswire May 6, 2024

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

PR Newswire April 10, 2024

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

PR Newswire April 8, 2024

Scinai leadership to attend BIO-Europe Spring 2024

PR Newswire March 12, 2024

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

PR Newswire February 29, 2024

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

PR Newswire February 13, 2024

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

PR Newswire January 25, 2024

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

PR Newswire January 4, 2024

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

PR Newswire January 4, 2024

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

PR Newswire December 29, 2023

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

PR Newswire December 27, 2023

Scinai Announces Promising Results in a Psoriatic Human Skin Model

PR Newswire December 12, 2023

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

PR Newswire December 11, 2023

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

PR Newswire November 29, 2023

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

PR Newswire November 20, 2023

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

GlobeNewswire November 6, 2023

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

GlobeNewswire November 3, 2023